Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The capsular polysaccharide of Neisseria meningitidis group Y is a major virulence factor and cell-surface antigen of the Gram-negative bacterium Neisseria meningitidis serogroup Y. Structurally, it is a partially O-acetylated copolymer composed of alternating units of N-acetylneuraminic acid (sialic acid) and D-glucose. This polysaccharide capsule plays a critical role in bacterial survival within the host by preventing opsonization and inhibiting complement-mediated phagocytosis, allowing the pathogen to evade the host's immune system. Neisseria meningitidis serogroup Y is a significant cause of invasive meningococcal disease, which can manifest as life-threatening meningitis, septicemia (meningococcemia), and pneumonia. As a therapeutic target, this capsular polysaccharide is utilized as an antigen in several meningococcal vaccines to stimulate active immunity. To overcome the poor immunogenicity of pure polysaccharides in infants and young children, the polysaccharide is typically conjugated to carrier proteins such as diphtheria toxoid, CRM197, or tetanus toxoid. Vaccination induces the production of serogroup-specific bactericidal antibodies that activate the classical complement pathway, leading to complement-mediated lysis and phagocytosis of the bacteria. Prominent vaccines targeting this antigen include Menactra, Menveo, Nimenrix, MenQuadfi, and the pentavalent vaccine Penbraya.
Active immunization. The capsular polysaccharide acts as an antigen that, when administered (often conjugated to a carrier protein to enhance T-cell dependent response), stimulates the host immune system to produce serogroup-specific bactericidal antibodies (IgG and IgM). These antibodies, in cooperation with the complement system, mediate complement-dependent bactericidal killing and opsonophagocytosis of Neisseria meningitidis serogroup Y bacteria, thereby preventing invasive meningococcal disease.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neisseria meningitidis group Y capsular polysaccharide (MenY-PS).